齊一生物小編報(bào)道：

日本讀賣(mài)新聞zui近刊登了一篇新聞稱(chēng)，中國(guó)科學(xué)界在干細(xì)胞研究領(lǐng)域發(fā)表的論文數(shù)已經(jīng)超過(guò)了日本，而這一領(lǐng)域一直被認(rèn)為是解決一些醫(yī)學(xué)重大難題如神經(jīng)退行性疾病藥物研發(fā)的突破點(diǎn)。這也使得中國(guó)在該領(lǐng)域發(fā)表的論文總數(shù)量一躍升至第二位。目前在干細(xì)胞研究領(lǐng)域發(fā)表論文數(shù)zui多的前三個(gè)國(guó)家依次是美國(guó)、中國(guó)和日本。據(jù)日本媒體報(bào)道，近年來(lái)中國(guó)在干細(xì)胞研究領(lǐng)域的各個(gè)方面都取得了長(zhǎng)足的進(jìn)步，這一進(jìn)步也直接體現(xiàn)在發(fā)表論文數(shù)上，而反觀日本學(xué)術(shù)界，近年來(lái)在該領(lǐng)域取得的成績(jī)就顯得乏善可陳，除了在人工誘導(dǎo)多能干細(xì)胞（iPS）領(lǐng)域占據(jù)優(yōu)勢(shì)以外，在其他干細(xì)胞研究領(lǐng)域的進(jìn)步都十分緩慢。

這一結(jié)論是日本媒體分析了2008年-2012年發(fā)表的超過(guò)17500篇干細(xì)胞領(lǐng)域相關(guān)論文后得出的，在這些研究中，來(lái)自美國(guó)研究機(jī)構(gòu)的成果多達(dá)5129項(xiàng)，而中國(guó)和日本分別發(fā)表了1640和1350篇論文。而在2004年-2009年之間，日本的成果數(shù)則位居第二。

同時(shí)日本媒體還統(tǒng)計(jì)了在干細(xì)胞領(lǐng)域取得成績(jī)zui顯著的前50家大學(xué)和研究機(jī)構(gòu)。其中美國(guó)的研究機(jī)構(gòu)幾乎占據(jù)了這份榜單的半壁江山，而加州大學(xué)和斯坦福大學(xué)則分居冠亞軍，傲視群雄。而日本則共有5家研究機(jī)構(gòu)上榜，其中京都大學(xué)位居第六位、東京大學(xué)位居第十四位。而中國(guó)則有七家科研單位上榜，其中以位居第十一位的中山大學(xué)*。

一直以來(lái)，日本在iPS領(lǐng)域都享有盛名，2012年山中伸彌就因?yàn)樵谠擃I(lǐng)域出色的研究而與英國(guó)的約翰戈登分享了諾貝爾生理學(xué)獎(jiǎng)。然而，zui近因?yàn)樾”７角缱拥热嗽贜ature上發(fā)表的研究成果涉嫌造假，也為日本的iPS乃至整個(gè)干細(xì)胞研究都蒙上了一層陰影。而事件的另一重要人物小保方晴子的導(dǎo)師，科學(xué)家笹井芳樹(shù)的自殺也為這一事件蒙上了一層悲劇色彩。

不過(guò)，盡管近年來(lái)中國(guó)學(xué)術(shù)界在干細(xì)胞研究領(lǐng)域取得了一定的進(jìn)展，但這卻不是我們沾沾自喜的時(shí)候，一方面是我們距離前面的美國(guó)仍有很大距離，另一方面我們必須正視在這一領(lǐng)域，中國(guó)的科學(xué)家并沒(méi)有多少重量級(jí)的研究成果。因此，在這一領(lǐng)域中，中國(guó)學(xué)術(shù)界仍然是任重道遠(yuǎn)。

詳細(xì)英文報(bào)道：

Japan fell below China in the number of articles published on stem cells, which are expected to lead to the practical realization of regenerative medicine treatments and products, slipping from second to third place, according to a survey report by the Japan Patent Office.

Amid increasingly fierce international competition in stem cell research, the United States, which tops the list, and China saw a steady increase in the number of articles in a wide range of research areas, while the number of articles in Japan grew at a sluggish pace in research areas other than induced pluripotent stem (iPS) cells, according to the report.

The office analyzed about 17,500 articles related to stem cell research published from 2008 to 2012 by using a database of the U.S. National Library of Medicine, in which medical papers from around the world are registered. Concerning the nationalities of the institutions to which the lead authors of the articles belonged, the United States came in first place, as the lead authors of 5,129 articles belonged to U.S. institutions. China came in second by increasing its number from the previous period to 1,640, and Japan placed third with 1,350.

In the previous survey covering the period from 2004 to 2009, Japan came in second place, but in the latest survey, Japan was overtaken by China, which had placed fourth in the previous survey.

By research institution, the University of California topped the list, followed by Stanford University, as institutions in the United States accounted for half of the top 50. For Japan, five research institutions were in the top 50, such as Kyoto University in sixth place and the University of Tokyo in 14th. However, Japan was outnumbered by China, as seven Chinese institutions were within the top 50, led by Sun Yat-sen University in 11th place.

By area of research, the number of articles on iPS cells in Japan increased 11 times over the period from 2008 to 2012. But the number of articles on mesenchymal stem cells, which can develop into bones or cardiac muscles, increased from 1.4 times to 2.5 times in Europe, the United States and China, while the figure in Japan remained flat.